![Finn Eggert Sørensen](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Finn Eggert Sørensen
No más puestos en curso
Historial de carrera de Finn Eggert Sørensen
Antiguos cargos conocidos de Finn Eggert Sørensen.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Neurokey A/S
![]() Neurokey A/S Pharmaceuticals: MajorHealth Technology Neurokey wants to become a leading drug development company in the critical care field. The drugs under development will one day help countless patients suffering from the effects of debilitating and potentially fatal cardiovascular and neurological; diseases. Neurokey will be first to market with reliable efficient and easily administered medication that will increase the survival rate for these patients and dramatically minimize the risk of permanent neurological damage. | Director/Miembro de la Junta | 07/07/2009 | 30/07/2010 |
Takeda A/S
![]() Takeda A/S Financial ConglomeratesFinance Takeda A/S engages in holding or owning of securities in other companies other than banks. The company was founded on January 4, 2005 and is headquartered in Taastrup, Denmark. | Presidente | - | - |
SERENDEX PHARMACEUTICALS A/S | Corporate Officer/Principal | 20/05/2014 | - |
Contera Pharma ApS
![]() Contera Pharma ApS Pharmaceuticals: MajorHealth Technology Contera Pharma ApS is a holding company that identifies and develops treatments for patients suffering from movement disorders. It develops drug candidates based on a combination of repositioning, combinations, and reformulations. The firm's lead project JM-010 is for treatment of dyskinesia associated with Parkinson's disease. It develops an approach of using a combination therapy to tackle clinically relevant synergistic pathways to obtain therapeutic effects which will generate efficacious therapeutic entities based on robust pre-clinical and clinical evidence. The company was founded by Mikael Søndergaard Thomsen and John Bondo Hansen in 2010 and is headquartered in Copenhagen, Denmark. | Corporate Officer/Principal | - | - |
Proteo Target ApS | Corporate Officer/Principal | - | - |
Benzon Pharma A/S | Corporate Officer/Principal | - | - |
Nordisk Gentofte A/S | Corporate Officer/Principal | 07/07/2009 | - |
Bok Holding A/S
![]() Bok Holding A/S BiotechnologyHealth Technology Bok Holding A/S is a holding company that operates as a biotechnology company that researches and develops cancer treatment solutions. It develops the ZAS platform technology which efficiently enhances the effect of current anti-cancer drugs and reduces toxicity. The firm employs molecular techniques commonly known as molecular breeding or directed enzyme evolution which can activate anti-cancer drugs. The company was founded by Zoran Gojkovic on November 22, 2001 and is headquartered in Gentofte, Denmark. | Presidente | - | - |
NTG NORDIC TRANSPORT GROUP A/S | Public Communications Contact | 13/02/2013 | - |
Corporate Officer/Principal | 01/01/2004 | 13/02/2013 |
Formación de Finn Eggert Sørensen.
Danmarks Farmaceutiske Universitet | Graduate Degree |
Estadísticas
Internacional
Dinamarca | 11 |
Operativa
Corporate Officer/Principal | 6 |
Public Communications Contact | 1 |
Chairman | 1 |
Sectorial
Health Technology | 5 |
Transportation | 2 |
Consumer Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
NTG NORDIC TRANSPORT GROUP A/S | Transportation |
Empresas privadas | 8 |
---|---|
Bok Holding A/S
![]() Bok Holding A/S BiotechnologyHealth Technology Bok Holding A/S is a holding company that operates as a biotechnology company that researches and develops cancer treatment solutions. It develops the ZAS platform technology which efficiently enhances the effect of current anti-cancer drugs and reduces toxicity. The firm employs molecular techniques commonly known as molecular breeding or directed enzyme evolution which can activate anti-cancer drugs. The company was founded by Zoran Gojkovic on November 22, 2001 and is headquartered in Gentofte, Denmark. | Health Technology |
Neurokey A/S
![]() Neurokey A/S Pharmaceuticals: MajorHealth Technology Neurokey wants to become a leading drug development company in the critical care field. The drugs under development will one day help countless patients suffering from the effects of debilitating and potentially fatal cardiovascular and neurological; diseases. Neurokey will be first to market with reliable efficient and easily administered medication that will increase the survival rate for these patients and dramatically minimize the risk of permanent neurological damage. | Health Technology |
Nordisk Gentofte A/S | |
Benzon Pharma A/S | |
Proteo Target ApS | |
Contera Pharma ApS
![]() Contera Pharma ApS Pharmaceuticals: MajorHealth Technology Contera Pharma ApS is a holding company that identifies and develops treatments for patients suffering from movement disorders. It develops drug candidates based on a combination of repositioning, combinations, and reformulations. The firm's lead project JM-010 is for treatment of dyskinesia associated with Parkinson's disease. It develops an approach of using a combination therapy to tackle clinically relevant synergistic pathways to obtain therapeutic effects which will generate efficacious therapeutic entities based on robust pre-clinical and clinical evidence. The company was founded by Mikael Søndergaard Thomsen and John Bondo Hansen in 2010 and is headquartered in Copenhagen, Denmark. | Health Technology |
Serendex Pharmaceuticals A/S
![]() Serendex Pharmaceuticals A/S Pharmaceuticals: MajorHealth Technology Serendex Pharmaceuticals A/S engages in the research and development of pharmaceuticals for respiratory conditions. It develops drugs to treat respiratory conditions such as Pulmonary Alveolar Proteinosis, Bronchiectasis, Cystic Fibrosis related lung infections and Diffuse Alveolar Hemorrhage. The company was founded by Lars Heslet on October 31, 2008 and is headquartered in Horsholm, Denmark. | Health Technology |
Takeda A/S
![]() Takeda A/S Financial ConglomeratesFinance Takeda A/S engages in holding or owning of securities in other companies other than banks. The company was founded on January 4, 2005 and is headquartered in Taastrup, Denmark. | Finance |
- Bolsa de valores
- Insiders
- Finn Eggert Sørensen
- Experiencia